|
|
|
|
|
|
|
|
|
22.06.26 - 14:06
|
Here Are Monday′s Best Wall Street Analyst Research Calls: Accenture, Apple, Boyd Gaming, BWX Technologies, Conoco-Phillips, Estee Lauder, Hut 8, Incyte, SpaceX, and More (24/7 Wall St.)
|
|
|
Pre-Market Stock Futures: Futures are trading mixed as we prepare to finish the last full week of the second quarter. We finished a wild holiday-shortened trading week last Thursday, as Friday was the federal Juneteenth holiday, and all major indices rebounded smartly from the Federal Reserve-induced sell-off on Wednesday. Details of the signed memorandum of ... Here Are Monday's Best Wall Street Analyst Research Calls: Accenture, Apple, Boyd Gaming, BWX Technologies, Conoco-Phillips, Estee Lauder, Hut 8, Incyte, SpaceX, and More...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.06.26 - 09:15
|
Incyte-Aktie: Verbesserte Perspektiven eröffnen Kurspotenzial (Sharedeals)
|
|
|
Die Aktie von Incyte hat sich in den vergangenen zwölf Monaten deutlich besser entwickelt als viele Wettbewerber aus dem Biotechnologiesektor, bewegte sich im laufenden Jahr bisher aber eher seitwärts. Nach mehreren wichtigen operativen Fortschritten verbessert sich nun auch die langfristige Investmentstory des Unternehmens spürbar. Neueste Entwicklungen stärken Ausblick Noch vor rund einem Monat überwogen bei […]
The post Incyte-Aktie: Verbesserte Perspektiven eröffnen Kurspotenzial first appeared on sharedeals.de....
|
|
|
|
|
09.06.26 - 20:39
|
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential (Benzinga)
|
|
|
Incyte to acquire Vega Therapeutics for $1.25 billion upfront, adding a rare bleeding disorder candidate with blockbuster potential in 2030s.
Latest Ratings for INCY
DateFirmActionFromTo Feb 2022SVB LeerinkDowngradesMarket PerformUnderperform Feb 2022Morgan StanleyMaintainsEqual-Weight Jan 2022RBC CapitalUpgradesSector PerformOutperform
View More Analyst Ratings for INCY
View the Latest Analyst Ratings
Importance Rank:
1
read more...
|
|
|
|
|
|
|
|
|
|
|
|
|
08.06.26 - 13:03
|
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders (Business Wire)
|
|
|
- Proposed acquisition to add VGA039, a novel investigational monoclonal antibody that targets Protein S in Phase 3 development for von Willebrand disease (VWD)
- Star Therapeutics to receive $1.25 billion upfront, with up to $750 million in additional payments upon achievement of sales milestones
- Incyte will host an analyst and investor call on Monday, June 8, 2026, at 8:00 a.m. ETWILMINGTON, Del.--(BUSINESS WIRE)--$INCY--Incyte (Nasdaq:INCY) announced today it has entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, for $1.25 billion. Star Therapeutics will be eligible to receive up to $750 million in additional payments upon the achievement of sales milestones, for total potential consideration of up to $2.0 billion subject to customary closing adjustments. The proposed acquisition would add VGA039, a novel monoclonal antibody, to Incyte's hematology portfolio.
Vega Therapeutics' lead candidate, VGA039, modulates Protein S to i...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
